Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 09 2019
Historique:
received: 28 01 2019
revised: 25 02 2019
accepted: 14 03 2019
pubmed: 2 4 2019
medline: 15 5 2020
entrez: 2 4 2019
Statut: ppublish

Résumé

The STICH trial showed superiority of coronary artery bypass plus medical treatment (CABG) over medical treatment alone (MED) in patients with left ventricular ejection fraction (LVEF) ≤35%. In previous publications, percutaneous coronary intervention (PCI) prior to CABG was associated with worse prognosis. The main purpose of this study was to analyse if prior PCI influenced outcomes in STICH. Patients in the STICH trial (n = 1212), followed for a median time of 9.8 years, were included in the present analyses. In the total population, 156 had a prior PCI (74 and 82, respectively, in the MED and CABG groups). In those with vs. without prior PCI, the adjusted hazard-ratios (aHRs) were 0.92 (95% CI = 0.74-1.15) for all-cause mortality, 0.85 (95% CI = 0.64-1.11) for CV mortality, and 1.43 (95% CI = 1.15-1.77) for CV hospitalization. In the group randomized to CABG without prior PCI, the aHRs were 0.82 (95% CI = 0.70-0.95) for all-cause mortality, 0.75 (95% CI = 0.62-0.90) for CV mortality and 0.67 (95% CI = 0.56-0.80) for CV hospitalization. In the group randomized to CABG with prior PCI, the aHRs were 0.76 (95% CI = 0.50-1.15) for all-cause mortality, 0.81 (95% CI = 0.49-1.36) for CV mortality and 0.61 (95% CI = 0.41-0.90) for CV hospitalization. There was no evidence of interaction between randomized treatment and prior PCI for any endpoint (all adjusted p > 0.05). In the STICH trial, prior PCI did not affect the outcomes of patients whether they were treated medically or surgically, and the superiority of CABG over MED remained unchanged regardless of prior PCI. Clinicaltrials.gov; Identifier: NCT00023595.

Sections du résumé

BACKGROUND
The STICH trial showed superiority of coronary artery bypass plus medical treatment (CABG) over medical treatment alone (MED) in patients with left ventricular ejection fraction (LVEF) ≤35%. In previous publications, percutaneous coronary intervention (PCI) prior to CABG was associated with worse prognosis.
OBJECTIVES
The main purpose of this study was to analyse if prior PCI influenced outcomes in STICH.
METHODS AND RESULTS
Patients in the STICH trial (n = 1212), followed for a median time of 9.8 years, were included in the present analyses. In the total population, 156 had a prior PCI (74 and 82, respectively, in the MED and CABG groups). In those with vs. without prior PCI, the adjusted hazard-ratios (aHRs) were 0.92 (95% CI = 0.74-1.15) for all-cause mortality, 0.85 (95% CI = 0.64-1.11) for CV mortality, and 1.43 (95% CI = 1.15-1.77) for CV hospitalization. In the group randomized to CABG without prior PCI, the aHRs were 0.82 (95% CI = 0.70-0.95) for all-cause mortality, 0.75 (95% CI = 0.62-0.90) for CV mortality and 0.67 (95% CI = 0.56-0.80) for CV hospitalization. In the group randomized to CABG with prior PCI, the aHRs were 0.76 (95% CI = 0.50-1.15) for all-cause mortality, 0.81 (95% CI = 0.49-1.36) for CV mortality and 0.61 (95% CI = 0.41-0.90) for CV hospitalization. There was no evidence of interaction between randomized treatment and prior PCI for any endpoint (all adjusted p > 0.05).
CONCLUSION
In the STICH trial, prior PCI did not affect the outcomes of patients whether they were treated medically or surgically, and the superiority of CABG over MED remained unchanged regardless of prior PCI.
CLINICAL TRIAL REGISTRATION
Clinicaltrials.gov; Identifier: NCT00023595.

Identifiants

pubmed: 30929973
pii: S0167-5273(19)30541-8
doi: 10.1016/j.ijcard.2019.03.029
pmc: PMC6579621
mid: NIHMS1525848
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT00023595']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

36-41

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL105853
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL069013
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL069015
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Références

Eur J Cardiothorac Surg. 2019 Feb 1;55(2):186-190
pubmed: 30388217
Surgery. 2012 Jul;152(1):5-11
pubmed: 22503323
J Am Coll Cardiol. 2017 May 2;69(17):2212-2241
pubmed: 28291663
Heart Lung Circ. 2013 Nov;22(11):940-5
pubmed: 23683716
Circulation. 2006 Jul 4;114(1 Suppl):I441-7
pubmed: 16820616
Circ Cardiovasc Interv. 2018 Feb;11(2):e005650
pubmed: 29440275
N Engl J Med. 1985 Jun 27;312(26):1665-71
pubmed: 3873614
Eur Heart J. 2014 Oct 1;35(37):2541-619
pubmed: 25173339
N Engl J Med. 2009 Mar 5;360(10):961-72
pubmed: 19228612
J Thorac Cardiovasc Surg. 2007 Dec;134(6):1540-7
pubmed: 18023680
J Thorac Cardiovasc Surg. 2015 May;149(5):1302-9
pubmed: 25772280
N Engl J Med. 1984 Nov 22;311(21):1333-9
pubmed: 6333636
Heart Vessels. 2016 Apr;31(4):457-64
pubmed: 25637043
Lancet. 2003 Jan 4;361(9351):13-20
pubmed: 12517460
Eur J Cardiothorac Surg. 2011 Jun;39(6):e164-9
pubmed: 21459592
Am J Cardiol. 2017 Jul 1;120(1):69-74
pubmed: 28483202
Eur Heart J. 2008 Mar;29(5):673-9
pubmed: 18285358
Ann Thorac Surg. 2017 Jul;104(1):56-61
pubmed: 28131427
Ann Thorac Surg. 2012 Jun;93(6):1956-62
pubmed: 22520830
N Engl J Med. 2011 Apr 28;364(17):1607-16
pubmed: 21463150
Ann Thorac Surg. 2016 Dec;102(6):1911-1918
pubmed: 27743636
Circulation. 2016 May 31;133(22):2132-40
pubmed: 27151532
Arq Bras Cardiol. 2012 Jul;99(1):586-95
pubmed: 22735865
N Engl J Med. 2016 Apr 21;374(16):1511-20
pubmed: 27040723
Circ Heart Fail. 2017 Jan;10(1):
pubmed: 28087687
Am Heart J. 2005 Nov;150(5):1026-31
pubmed: 16290991
J Card Surg. 2015 Apr;30(4):313-8
pubmed: 25644217

Auteurs

Jose C Nicolau (JC)

Instituto do Coracao (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil. Electronic address: jose.nicolau@incor.usp.br.

Susanna R Stevens (SR)

Duke Clinical Research Institute and Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.

Hussein R Al-Khalidi (HR)

Duke Clinical Research Institute and Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.

Fabio B Jatene (FB)

Instituto do Coracao (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Remo H M Furtado (RHM)

Instituto do Coracao (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Luis A O Dallan (LAO)

Instituto do Coracao (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Luiz A F Lisboa (LAF)

Instituto do Coracao (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Patrice Desvigne-Nickens (P)

Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Haissam Haddad (H)

Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

E Marc Jolicoeur (EM)

Montreal Heart Institute, Université de Montréal, Quebec, Canada.

Mark C Petrie (MC)

BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.

Torsten Doenst (T)

Department of Cardiothoracic Surgery, University of Jena, Jena, Germany.

Robert E Michler (RE)

Department of Cardiothoracic Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY, USA.

E Magnus Ohman (EM)

Duke Clinical Research Institute and Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.

Jyotsna Maddury (J)

Department of Cardiology, Nizams Institute of Medical Sciences, Hyderabad, India.

Imtiaz Ali (I)

Libin Cardiovascular Institute of Alberta, University of Calgary, Foothills Medical Centre, Calgary, Alberta, Canada.

Marek A Deja (MA)

Department of Cardiac Surgery, Medical University of Silesia, Katowice, Poland.

Jean L Rouleau (JL)

Montreal Heart Institute, Université de Montréal, Quebec, Canada.

Eric J Velazquez (EJ)

Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.

James A Hill (JA)

Department of Medicine, University of Florida, Gainesville, FL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH